Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Key Points

• Wall Street Zen upgraded Oramed Pharmaceuticals from “hold” to “buy,” although MarketBeat’s overall analyst rating remains “Hold” based on one analyst.
• Oramed shares opened at $4.48, with a market capitalization of $186.35 million and a 52-week range of $1.98 to $5.19. The company reported a quarterly loss of $0.09 per share, missing the $0.43 consensus estimate.
• Company insiders sold shares in July, including the CFO’s $330,854 sale and the COO’s $611,020 sale; insiders collectively own 20.77% of Oramed, while institutional investors own 12.73%.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of "Hold".

Oramed Pharmaceuticals Price Performance

NASDAQ:ORMP opened at $4.48 on Friday. The firm has a market capitalization of $186.35 million, a PE ratio of 1.09 and a beta of 1.22. The business's fifty day moving average price is $4.18 and its 200 day moving average price is $3.84. Oramed Pharmaceuticals has a 12 month low of $1.98 and a 12 month high of $5.19.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.52). As a group, equities analysts anticipate that Oramed Pharmaceuticals will post 1.24 EPS for the current year.

Insider Activity

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 73,360 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the completion of the transaction, the chief financial officer owned 671,785 shares in the company, valued at approximately $3,029,750.35. This represents a 9.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joshua Hexter sold 137,000 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total transaction of $611,020.00. Following the transaction, the chief operating officer owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 20.77% of the company's stock.

Institutional Trading of Oramed Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company's stock valued at $497,000 after buying an additional 3,909 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Oramed Pharmaceuticals by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company's stock worth $538,000 after acquiring an additional 7,738 shares in the last quarter. XTX Topco Ltd lifted its holdings in Oramed Pharmaceuticals by 59.9% in the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company's stock valued at $109,000 after acquiring an additional 14,297 shares during the period. Kathmere Capital Management LLC purchased a new stake in shares of Oramed Pharmaceuticals during the 1st quarter worth $51,000. Finally, Jane Street Group LLC grew its stake in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after purchasing an additional 17,510 shares during the period. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed's platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company's lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source